HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tadashi Kimura Selected Research

Adjuvant Radiotherapy

3/2013Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
10/2012Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma.
10/2012Comparison of the prognoses of FIGO stage I to stage II adenosquamous carcinoma and adenocarcinoma of the uterine cervix treated with radical hysterectomy.
3/2012The prognostic significance of multiple pelvic node metastases in cervical cancer patients treated with radical hysterectomy plus adjuvant chemoradiotherapy.
11/2011Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tadashi Kimura Research Topics

Disease

133Neoplasms (Cancer)
03/2024 - 06/2003
82Uterine Cervical Neoplasms (Cancer of the Cervix)
12/2023 - 05/2009
51Ovarian Neoplasms (Ovarian Cancer)
04/2024 - 03/2007
26Endometrial Neoplasms (Endometrial Cancer)
06/2022 - 05/2008
25Carcinoma (Carcinomatosis)
11/2018 - 04/2007
16Ovarian Epithelial Carcinoma
06/2023 - 11/2009
15Neoplasm Metastasis (Metastasis)
03/2024 - 05/2005
14Pre-Eclampsia (Preeclampsia)
02/2022 - 04/2009
12Hemorrhage
04/2022 - 09/2008
11Adenocarcinoma
12/2023 - 09/2010
10Placenta Accreta
01/2021 - 01/2012
8Leiomyoma (Uterine Fibroids)
01/2016 - 01/2008
7Placenta Previa
01/2023 - 01/2012
7Infections
12/2022 - 05/2010
7Fetal Growth Retardation (Intrauterine Growth Retardation)
09/2022 - 05/2014
7Postpartum Hemorrhage
09/2021 - 10/2018
7Hypoxia (Hypoxemia)
01/2020 - 04/2009
6Ascites
10/2022 - 10/2002
6Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2018 - 04/2010
6Endometrioid Carcinoma
04/2016 - 05/2010
5Carcinogenesis
01/2023 - 05/2008
5Disease Progression
01/2022 - 04/2010
5Cysts
11/2021 - 12/2005
4Papillomavirus Infections
03/2024 - 08/2016
4Lymphatic Metastasis
02/2023 - 01/2011
4Inflammation (Inflammations)
01/2023 - 11/2013
4Premature Birth (Birth, Premature)
01/2023 - 11/2004
4Chorioamnionitis
03/2016 - 03/2004
4Colorectal Neoplasms (Colorectal Cancer)
01/2016 - 02/2010
3Systemic Lupus Erythematosus (Libman-Sacks Disease)
04/2024 - 02/2018
3Uterine Cervical Dysplasia
12/2022 - 05/2012
3Endometriosis
01/2022 - 08/2016
3Gestational Diabetes (Gestational Diabetes Mellitus)
03/2021 - 11/2007
3Choriocarcinoma
01/2018 - 04/2009
3Osteoporosis
01/2017 - 01/2009

Drug/Important Bio-Agent (IBA)

19PlatinumIBA
04/2023 - 05/2009
18Paclitaxel (Taxol)FDA LinkGeneric
05/2023 - 05/2009
17Papillomavirus Vaccines (HPV Vaccines)IBA
03/2024 - 06/2015
17Proteins (Proteins, Gene)FDA Link
08/2019 - 10/2002
16Carboplatin (JM8)FDA LinkGeneric
05/2022 - 05/2009
13Cisplatin (Platino)FDA LinkGeneric
09/2021 - 12/2008
12VaccinesIBA
03/2024 - 11/2009
11AntigensIBA
01/2022 - 11/2007
11Granulocyte Colony-Stimulating Factor (G-CSF)IBA
01/2021 - 04/2010
10SuspensionsIBA
10/2022 - 05/2005
10Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2018 - 03/2007
9Indicators and Reagents (Reagents)IBA
09/2021 - 07/2011
9Biomarkers (Surrogate Marker)IBA
01/2020 - 06/2010
8MicroRNAs (MicroRNA)IBA
01/2020 - 05/2013
7Monoclonal AntibodiesIBA
06/2022 - 12/2008
7Irinotecan (Camptosar)FDA LinkGeneric
01/2019 - 12/2011
7taxaneIBA
10/2018 - 05/2009
6CytokinesIBA
01/2023 - 11/2013
6Tyrosine (L-Tyrosine)FDA Link
01/2019 - 04/2007
6nedaplatinIBA
08/2015 - 12/2009
5AntibodiesIBA
02/2024 - 10/2014
5Peptides (Polypeptides)IBA
01/2023 - 11/2009
5Estrogens (Estrogen)FDA Link
01/2023 - 01/2012
5Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
02/2022 - 01/2011
5Interleukin-6 (Interleukin 6)IBA
01/2019 - 06/2010
4Lipoprotein Receptors (Lipoprotein Receptor)IBA
02/2024 - 01/2021
4Bevacizumab (Avastin)FDA Link
10/2023 - 12/2008
4DNA (Deoxyribonucleic Acid)IBA
01/2023 - 02/2010
4Immunoconjugates (Immunoconjugate)IBA
01/2023 - 01/2018
4Oxytocin (Pitocin)FDA LinkGeneric
09/2022 - 02/2009
4AnthracyclinesIBA
05/2022 - 04/2011
4Tadalafil (Cialis)FDA Link
11/2021 - 10/2018
4Neutralizing AntibodiesIBA
03/2019 - 07/2014
4IntegrinsIBA
10/2017 - 01/2012
3RNA (Ribonucleic Acid)IBA
10/2023 - 07/2022
3Immunoglobulin G (IgG)IBA
10/2023 - 01/2022
3Epirubicin (Ellence)FDA LinkGeneric
05/2022 - 04/2011
3Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA
02/2022 - 01/2013
3Hemoglobins (Hemoglobin)IBA
01/2022 - 03/2015
3C-Reactive ProteinIBA
01/2022 - 05/2010
3GemcitabineFDA Link
11/2021 - 09/2012
3LipidsIBA
08/2019 - 02/2015
3EverolimusFDA Link
04/2016 - 09/2009

Therapy/Procedure

61Therapeutics
01/2023 - 01/2008
40Drug Therapy (Chemotherapy)
03/2024 - 05/2009
35Hysterectomy
07/2023 - 06/2003
29Radiotherapy
12/2022 - 05/2009
12Lymph Node Excision (Lymph Node Dissection)
02/2023 - 10/2012
12Chemoradiotherapy
09/2021 - 12/2009
8Brachytherapy
05/2021 - 01/2010
7Immunotherapy
02/2024 - 11/2009
7Conservative Treatment
01/2022 - 01/2006
7Cesarean Section (Caesarean Section)
02/2017 - 01/2011
6Aftercare (After-Treatment)
12/2023 - 08/2010
6Combination Drug Therapy (Combination Chemotherapy)
10/2018 - 12/2011
5Uterine Artery Embolization
01/2021 - 01/2016
5Adjuvant Radiotherapy
03/2013 - 11/2011
4Cytoreduction Surgical Procedures
10/2012 - 03/2010
3Sutures (Suture)
01/2023 - 03/2019
3Laparotomy
03/2022 - 03/2011
3Kampo Medicine (Kampo)
01/2022 - 01/2018
3Salpingo-oophorectomy
11/2019 - 05/2015
3Consolidation Chemotherapy
01/2017 - 12/2011
3Salvage Therapy
11/2016 - 10/2013
3Uterine Myomectomy
06/2016 - 01/2008